Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update. Recent Corporate Highlights CORDStrom™ Platform:The CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB) is on target to file an MAA submission in the UK mid-summer, followed shortly thereafter by anticipated EMA and FDA regulatory submissions. Hosted KOL led webinar focused on the latest results from the MissionEB Phase III clinical trial highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB. Announced the publishing...

Reports Q4 2025 GAAP Net Loss of $15.5 Million and Full Year Net Loss of $43.9 Million Calculates Q4 2025 Adjusted Net Loss of $8.7 Million (Non-GAAP) and Full Year Adjusted Net Loss of $18.5 Million (Non-GAAP) Recognized $4.2 Million in Other Income for the Full Year, primarily from California Energy Commission Grant Ended Year with $9.6 Million in Cash and Cash EquivalentsCARLSBAD, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Aptera Motors Corp. (NASDAQ: SEV) (“Aptera” or the “Company”), a solar mobility company advancing ultra-efficient transportation, today reported its financial results for the fourth quarter and full year ended December 31, 2025. “Our fourth quarter capped a transformative year for Aptera as we transitioned to a publicly traded company and began standing up our validation assembly line,” said Chris Anthony,...

Commercial inflection with >$50 million in bookings in early 2026 Operating companies advancing independent capital formation, materially reducing reliance on Innventure’s balance sheet Consolidated G&A declined 61% in 4Q25 compared to 4Q24, reflecting sustained cost discipline since the public listing ORLANDO, Fla., March 30, 2026 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure”), an industrial growth conglomerate, today announced financial results for the quarter and year ended December 31, 2025. “The fourth quarter capped a successful 2025 for Innventure. More importantly, the early months of 2026 demonstrate Innventure is at a true commercial inflection point. Our operating companies are executing simultaneously, converting demand into bookings, raising capital independently, and materially reducing the capital...

NANCHANG, China, March 30, 2026 (GLOBE NEWSWIRE) — Ruanyun Edai Technology Inc. (NASDAQ: RYET) (“Ruanyun” or the “Company”), an innovative artificial intelligence (“AI”) driven education technology company focused on developing and delivering AI-enabled digital education platforms, including intelligent learning tools, assessment platforms, and adaptive learning systems, today announced its unaudited interim financial results for the six months ended September 30, 2025. 1H 2026 (Six Months Ended September 30, 2025) Unaudited Interim Financial HighlightsOur revenue was $366,256 for the six months ended September 30, 2025, compared with $4,109,689 for the six months ended September 30, 2024, representing a decrease of 91.1%. Gross margin was 26.2% for the six months ended September 30, 2025, compared with 42.1% for the six months...

RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its financial results for the full year and fourth quarter ended December 31, 2025, and is providing a business update to shareholders. Shaun Bagai, Chief...

NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business UpdatesGenerated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the period Raised $29.9 million in 2025 through the Company’s ATM programs, with proceeds used primarily to purchase SOL on an net asset value (“NAV”)/share accretive basis Repurchased $3.4 million of common stock in 2026, funded primarily through the sale of SOL, while NAV/share...

RICHMOND, Va., March 30, 2026 (GLOBE NEWSWIRE) — ARKO Petroleum Corp. (Nasdaq: APC) (“APC” or the “Company”), one of the largest wholesale fuel distributors in the United States, today announced financial results for the fourth quarter and the full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Key Highlights (vs. Year-Ago Period) 1,2Net income for the quarter increased to $8.1 million compared to $7.5 million.  For the year, net income was $32.7 million compared to $40.2 million. Adjusted EBITDA for the quarter increased to $36.9 million compared to $35.4 million.  For the year, Adjusted EBITDA was $143.5 million compared to $139.2 million.   Net cash provided by operating activities for the quarter was $16.4 million compared to $35.1 million.  For the year, net cash provided by operating activities was $79.6...

– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve...

Revenue growth expected to accelerate in 2026 Management to host conference call today at 5 p.m. ET to review results and discuss outlook PROVIDENCE, R.I., March 30, 2026 (GLOBE NEWSWIRE) — via IBN — Beeline Holdings, Inc. (Nasdaq: BLNE), the emerging digital mortgage lender and fractional equity platform, today announces financial results for the fourth quarter ended December 31, 2025.  Q4 2025 Financial Highlights Net revenue of $2.5 million, up 127% year-over-year and 8.3% sequentially  Q4 2025 origination volume of $84.7 million, up 44% year-over-yearOperating expenses increased, primarily reflecting $4.2 million in non-cash stock-based compensation; excluding this, operating expenses increased 19% on 127% revenue growth 1Launched BeelineEquity platform and closed initial transactions recorded on the Blockchain...

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration Strengthened leadership team with addition of new Chief Medical Officer and senior appointments bolstering cardiac expertise Cash, cash equivalents...